Guangzhou LBP Medicine Science & Technology Co., Ltd.
SSE:688393.SS
28.33 (CNY) • At close June 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 72.543 | 118.113 | 124.61 | 125.442 | 101.469 | 142.784 | 143.553 | 120.209 | 90.745 | 133.056 | 131.8 | 122.435 | 120.09 | 111.907 | 114.706 | 112.868 | 99.508 | 110.794 | 119.819 | 106.358 | 38.462 | 104.904 | 94.349 | 85.149 | 70.758 |
| Cost of Revenue
| 27.59 | 42.897 | 44.213 | 46.825 | 28.287 | 47.661 | 49.477 | 33.249 | 26.287 | 41.892 | 37.487 | 32.401 | 34.97 | 25.271 | 27.337 | 22.018 | 22.321 | 25.957 | 21.219 | 21.649 | 7.139 | 18.362 | 14.164 | 13.18 | 12.237 |
| Gross Profit
| 44.953 | 75.216 | 80.397 | 78.617 | 73.182 | 95.123 | 94.075 | 86.961 | 64.458 | 91.163 | 94.314 | 90.034 | 85.12 | 86.636 | 87.369 | 90.85 | 77.187 | 84.837 | 98.599 | 84.71 | 31.323 | 86.542 | 80.185 | 71.969 | 58.522 |
| Gross Profit Ratio
| 0.62 | 0.637 | 0.645 | 0.627 | 0.721 | 0.666 | 0.655 | 0.723 | 0.71 | 0.685 | 0.716 | 0.735 | 0.709 | 0.774 | 0.762 | 0.805 | 0.776 | 0.766 | 0.823 | 0.796 | 0.814 | 0.825 | 0.85 | 0.845 | 0.827 |
| Reseach & Development Expenses
| 9.284 | 14.387 | 7.567 | 12.487 | 8.741 | 18.082 | 16.668 | 15.094 | 12.843 | 20.282 | 15.835 | 16.464 | 14.813 | 10.878 | 19.805 | 9.148 | 6.072 | 10.279 | 6.189 | 7.013 | 4.252 | 8.305 | 5.311 | 4.779 | 3.463 |
| General & Administrative Expenses
| 17.557 | -61.179 | 56.835 | -11.771 | 21.65 | -40.768 | 47.425 | -7.231 | 18.626 | -33.346 | 44.683 | -5.309 | 14.422 | -6.834 | 21.338 | -4.144 | 8.55 | -10.916 | 10.135 | 1.655 | 0.842 | -13.609 | 5.837 | 2.228 | 0.929 |
| Selling & Marketing Expenses
| 37.38 | -28.936 | 69.553 | 51.63 | 43.232 | 57.073 | 40.408 | 46.298 | 38.884 | 53.292 | 51.409 | 45.801 | 35.473 | 49.126 | 43.775 | 48.422 | 38.271 | 56.487 | 41.291 | 43.604 | 12.174 | 55.164 | 34.926 | 41.604 | 30.189 |
| SG&A
| 54.937 | -90.115 | 133.556 | 68.569 | 64.882 | 16.305 | 87.832 | 39.068 | 57.509 | 19.947 | 96.092 | 40.491 | 49.895 | 42.293 | 65.113 | 44.278 | 46.821 | 45.571 | 51.426 | 45.258 | 13.016 | 41.556 | 40.763 | 43.832 | 31.119 |
| Other Expenses
| -4.809 | 160.209 | 0 | -0.022 | -0.276 | -0.71 | -2.454 | -1.794 | -1.968 | 55.086 | -24.522 | 24.46 | 0.183 | -0.496 | 0.087 | 0.241 | -0.048 | 0.183 | -0.485 | -0.039 | -0.002 | -0.958 | -0.314 | -0.254 | -0.023 |
| Operating Expenses
| 59.412 | 85.667 | 67.19 | 81.078 | 70.745 | 93.597 | 77.176 | 81.288 | 68.384 | 95.315 | 87.405 | 81.415 | 64.89 | 86.913 | 71.863 | 65.869 | 50.352 | 66.952 | 57.944 | 57.332 | 21.501 | 68.668 | 46.512 | 54.653 | 39.111 |
| Operating Income
| -14.459 | -10.451 | 13.207 | -2.461 | 3.921 | -2.88 | 17.247 | 6.737 | 0.408 | -10.509 | 4.671 | 9.249 | 21.426 | 4.298 | 26.792 | 26.546 | 31.304 | 20.968 | 41.119 | 27.38 | 10.729 | 17.889 | 33.806 | 18.389 | 18.712 |
| Operating Income Ratio
| -0.199 | -0.088 | 0.106 | -0.02 | 0.039 | -0.02 | 0.12 | 0.056 | 0.004 | -0.079 | 0.035 | 0.076 | 0.178 | 0.038 | 0.234 | 0.235 | 0.315 | 0.189 | 0.343 | 0.257 | 0.279 | 0.171 | 0.358 | 0.216 | 0.264 |
| Total Other Income Expenses Net
| -0.191 | -0.02 | -1.218 | -0.053 | -0.276 | -0.71 | -2.454 | -1.794 | 0.294 | 0.708 | -0.163 | 4.157 | -0.44 | -0.496 | 0.087 | 0.241 | -0.048 | 0.183 | -0.485 | -0.039 | -0.002 | -0.958 | -0.314 | -0.254 | -0.023 |
| Income Before Tax
| -14.65 | -10.471 | 11.989 | 4.423 | 3.645 | -3.59 | 14.794 | 4.943 | 0.702 | -9.801 | 4.508 | 13.097 | 20.987 | 3.802 | 26.879 | 26.787 | 31.256 | 21.15 | 40.634 | 27.341 | 10.727 | 16.931 | 33.492 | 18.135 | 18.689 |
| Income Before Tax Ratio
| -0.202 | -0.089 | 0.096 | 0.035 | 0.036 | -0.025 | 0.103 | 0.041 | 0.008 | -0.074 | 0.034 | 0.107 | 0.175 | 0.034 | 0.234 | 0.237 | 0.314 | 0.191 | 0.339 | 0.257 | 0.279 | 0.161 | 0.355 | 0.213 | 0.264 |
| Income Tax Expense
| -2.4 | -2.185 | 1.092 | -4.236 | -0.137 | -5.778 | 0.408 | 0.333 | 0.868 | -5.101 | 0.052 | 0.845 | 3.665 | 0.956 | 3.647 | 3.816 | 5.022 | 3.181 | 6.995 | 4.392 | 1.663 | 3.572 | 4.949 | 2.88 | 3.043 |
| Net Income
| -11.064 | -8.339 | 13.268 | 8.373 | 7.989 | 2.463 | 19.49 | 10.285 | -0.166 | -4.7 | 4.456 | 12.252 | 19.624 | 5.261 | 23.634 | 24.216 | 26.665 | 18.37 | 33.78 | 22.716 | 9.881 | 13.744 | 28.599 | 15.933 | 15.714 |
| Net Income Ratio
| -0.153 | -0.071 | 0.106 | 0.067 | 0.079 | 0.017 | 0.136 | 0.086 | -0.002 | -0.035 | 0.034 | 0.1 | 0.163 | 0.047 | 0.206 | 0.215 | 0.268 | 0.166 | 0.282 | 0.214 | 0.257 | 0.131 | 0.303 | 0.187 | 0.222 |
| EPS
| -0.12 | -0.089 | 0.14 | 0.09 | 0.09 | 0.029 | 0.21 | 0.11 | -0.002 | -0.05 | 0.048 | 0.13 | 0.21 | 0.027 | 0.26 | 0.26 | 0.29 | 0.23 | 0.43 | 0.32 | 0.14 | 0.2 | 0.41 | 0.22 | 0.22 |
| EPS Diluted
| -0.12 | -0.085 | 0.14 | 0.09 | 0.08 | 0.029 | 0.2 | 0.11 | -0.002 | -0.05 | 0.048 | 0.13 | 0.21 | 0.026 | 0.26 | 0.26 | 0.29 | 0.23 | 0.43 | 0.32 | 0.14 | 0.2 | 0.41 | 0.22 | 0.22 |
| EBITDA
| -14.604 | 0.888 | 12.113 | 17.024 | 16.005 | 9.674 | 27.734 | 16.846 | 12.084 | 2.614 | 15.859 | 22.588 | 30.185 | 11.654 | 34.732 | 29.953 | 34.362 | 21.15 | 41.598 | 29.017 | 12.442 | 17.873 | 36.395 | 20.28 | 21.131 |
| EBITDA Ratio
| -0.201 | 0.008 | 0.097 | 0.136 | 0.158 | 0.068 | 0.193 | 0.14 | 0.133 | 0.02 | 0.12 | 0.184 | 0.251 | 0.104 | 0.303 | 0.265 | 0.345 | 0.191 | 0.347 | 0.273 | 0.324 | 0.17 | 0.386 | 0.238 | 0.299 |